| $376M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $99M |
Buys | $40,355 | 5 | 12 |
Sells | $4,503,604 | 37 | 88 |
| FREEMAN KEVIN D | director | 2 | $34,009 | 0 | $0 | $34,009 |
| ELDRED KARY | director | 3 | $6,346 | 0 | $0 | $6,346 |
| CALLICUTT JACK W | Chief Financial Officer | 0 | $0 | 10 | $530,140 | $-530,140 |
| Jamil Khurram | Chief Medical Officer | 0 | $0 | 7 | $642,985 | $-642,985 |
| LEWIS JOEL | President and CEO | 0 | $0 | 11 | $709,585 | $-709,585 |
| Shlevin Harold H. | director | 0 | $0 | 5 | $1.29M | $-1.29M |
| 10X Fund, L.P. | 10 percent owner | 0 | $0 | 4 | $1.34M | $-1.34M |
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Over the last 12 months, insiders at Galectin Therapeutics Inc. have bought $40,355 and sold $4.5M worth of Galectin Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Galectin Therapeutics Inc. have bought $58,302 and sold $998,698 worth of stock each year.
Highest buying activity among insiders over the last 12 months: FREEMAN KEVIN D (director) — $34,009. ELDRED KARY (director) — $6,346.
The last purchase of 300 shares for transaction amount of $810 was made by ELDRED KARY (director) on 2026‑02‑06.
| 2026-05-26 | Sale | Jamil Khurram | Chief Medical Officer | 568 0.001% | $3.10 | $1,761 | -18.69% | |
| 2026-02-06 | ELDRED KARY | director | 300 0.0004% | $2.70 | $810 | -7.86% | ||
| 2026-01-06 | Sale | LEWIS JOEL | President and CEO | 37,698 0.054% | $3.58 | $134,853 | -20.00% | |
| 2026-01-06 | Sale | CALLICUTT JACK W | Chief Financial Officer | 20,354 0.0299% | $3.67 | $74,695 | -20.00% | |
| 2026-01-06 | Sale | Jamil Khurram | Chief Medical Officer | 21,446 0.0313% | $3.65 | $78,205 | -20.00% | |
| 2026-01-05 | Sale | LEWIS JOEL | President and CEO | 27,731 0.0434% | $3.91 | $108,342 | -28.87% | |
| 2026-01-05 | Sale | CALLICUTT JACK W | Chief Financial Officer | 25,732 0.0401% | $3.90 | $100,298 | -28.87% | |
| 2026-01-05 | Sale | Jamil Khurram | Chief Medical Officer | 25,499 0.0398% | $3.90 | $99,408 | -28.87% | |
| 2026-01-02 | Sale | LEWIS JOEL | President and CEO | 18,571 0.0291% | $4.20 | $77,939 | -31.85% | |
| 2026-01-02 | Sale | CALLICUTT JACK W | Chief Financial Officer | 13,914 0.0218% | $4.20 | $58,394 | -31.85% | |
| 2026-01-02 | Sale | Jamil Khurram | Chief Medical Officer | 13,055 0.0205% | $4.20 | $54,789 | -31.85% | |
| 2025-12-31 | Sale | Jamil Khurram | Chief Medical Officer | 8,125 0.0126% | $4.07 | $33,089 | -33.65% | |
| 2025-12-23 | ELDRED KARY | director | 700 0.001% | $3.73 | $2,611 | -29.95% | ||
| 2025-12-23 | FREEMAN KEVIN D | director | 5,500 0.0075% | $3.55 | $19,514 | -29.95% | ||
| 2025-12-17 | Sale | LEWIS JOEL | President and CEO | 7,829 0.0133% | $7.06 | $55,241 | -56.72% | |
| 2025-12-17 | Sale | Shlevin Harold H. | director | 24,499 0.0414% | $7.04 | $172,424 | -56.72% | |
| 2025-12-17 | Sale | Jamil Khurram | Chief Medical Officer | 8,500 0.0144% | $7.04 | $59,840 | -56.72% | |
| 2025-12-16 | Sale | 10X Fund, L.P. | 10 percent owner | 30,681 0.0512% | $6.66 | $204,335 | -54.84% | |
| 2025-12-15 | Sale | Shlevin Harold H. | director | 8,417 0.0127% | $6.30 | $53,027 | -56.91% | |
| 2025-12-12 | Sale | Shlevin Harold H. | director | 19,793 0.0309% | $6.27 | $124,181 | -55.04% |
| 10X Fund, L.P. | 10 percent owner | 5614457 8.5252% | $14.65M | 0 | 42 | |
| LEWIS JOEL | President and CEO | 832592 1.2642% | $2.17M | 7 | 12 | <0.0001% |
| ELDRED KARY | director | 65682 0.0997% | $171,430.02 | 13 | 0 | +24.92% |
| FREEMAN KEVIN D | director | 55269 0.0839% | $144,252.09 | 31 | 0 | +3.31% |
| CALLICUTT JACK W | Chief Financial Officer | 7614 0.0116% | $19,872.54 | 4 | 18 | <0.0001% |
| Shlevin Harold H. | director | 6500 0.0099% | $16,965.00 | 2 | 15 | +120% |
| Jamil Khurram | Chief Medical Officer | 0 0% | $0 | 0 | 8 | |
| Martin Rod D | director | 9357422 14.2087% | $24.42M | 1 | 4 | <0.0001% |
| Uihlein Richard E | 7893191 11.9854% | $20.6M | 6 | 0 | <0.0001% | |
| CZIRR JAMES C | 10 percent owner | 5922207 8.9925% | $15.46M | 3 | 30 | <0.0001% |
| FIRTEL BURTON C | director | 129000 0.1959% | $336,690.00 | 3 | 0 | +32.75% |
| ROME JERALD K | director | 117344 0.1782% | $306,267.84 | 2 | 0 | +11.02% |
| Greenberg Arthur | director | 109445 0.1662% | $285,651.45 | 6 | 0 | <0.0001% |
| TRABER PETER G | President & CEO | 107333 0.163% | $280,139.13 | 11 | 2 | +22.8% |
| Prelack Steven | director | 87219 0.1324% | $227,641.59 | 0 | 1 | |
| OMENN GILBERT S | director | 66769 0.1014% | $174,267.09 | 1 | 2 | <0.0001% |
| SMITH DAVID H | director | 63500 0.0964% | $165,735.00 | 1 | 0 | <0.0001% |
| AMELIO GILBERT F | director | 60614 0.092% | $158,202.54 | 1 | 6 | +7.71% |
| Zordani Richard A. Jr. | director | 42083 0.0639% | $109,836.63 | 7 | 0 | +8.59% |
| CHRISTIAN MILDRED S | director | 27500 0.0418% | $71,775.00 | 1 | 0 | <0.0001% |
| CONAWAY DALE H | director | 22806 0.0346% | $59,523.66 | 4 | 0 | <0.0001% |
| MAULDIN JOHN F | director | 18074 0.0274% | $47,173.14 | 12 | 0 | +77.12% |
| CHRISTOPHER DAVID A | FORMER CFO & TREASURER | 16629 0.0253% | $43,401.69 | 0 | 2 | |
| Rubin Marc | director | 13581 0.0206% | $35,446.41 | 3 | 4 | +24.3% |
| MCGAULEY THOMAS | Chief Financial Officer | 10000 0.0152% | $26,100.00 | 1 | 0 | <0.0001% |
| PRESSLER HERMAN PAUL | director | 9500 0.0144% | $24,795.00 | 1 | 0 | <0.0001% |
| PLATT DAVID | Chairman & CEO | 6000 0.0091% | $15,660.00 | 3 | 1 | +15% |
| FOLEY MAUREEN | Chief Operating Officer | 5000 0.0076% | $13,050.00 | 1 | 0 | +26.27% |
| Gourzis James Theophile | director | 2000 0.003% | $5,220.00 | 1 | 0 | 0% |
| ZUCCONI THEODORE DANIEL | director | 1083 0.0016% | $2,826.63 | 3 | 1 | +8.35% |
| Schwartz Elissa J. | 1000 0.0015% | $2,610.00 | 1 | 0 | <0.0001% |
Galectin Therapeutics Inc. (GALT) | $22,693,451 | 105 | 8.15% | $171.89M |
$66,137,559 | 49 | 6.29% | $145.75M | |
$7,147,964 | 34 | 24.77% | $155.52M | |
$18,752,549 | 33 | -28.39% | $149.57M | |
$47,438,336 | 33 | -21.38% | $181.44M | |
$448,999,793 | 15 | -19.99% | $197.47M | |
$4,701,608 | 14 | -4.34% | $165.17M | |
$19,167,169 | 10 | 28.48% | $192.1M | |
$344,394 | 8 | -22.26% | $164.64M | |
$22,090,972 | 7 | -3.49% | $156.33M | |
$99,355,998 | 7 | -65.74% | $143.56M | |
$36,049,976 | 5 | -3.82% | $174.75M | |
$32,007,657 | 4 | -45.65% | $193.92M | |
$32,289,200 | 3 | -5.46% | $174.31M | |
$193,101 | 3 | -25.20% | $192.48M | |
$16,003,671 | 3 | 55.38% | $173.82M | |
$12,750 | 2 | -39.73% | $154.39M | |
$12,498 | 2 | 39.61% | $184.53M | |
$86,200 | 1 | -19.57% | $169.77M |
| Increased Positions | 52 | +53.06% | 2M | +20.62% |
| Decreased Positions | 37 | -37.76% | 1M | -11.39% |
| New Positions | 24 | New | 1M | New |
| Sold Out Positions | 15 | Sold Out | 566,757 | Sold Out |
| Total Postitions | 113 | +15.31% | 12M | +9.23% |
| Vanguard Group Inc | $9,104.00 | 3.51% | 2.25M | +63,419 | +2.9% | 2025-09-30 |
| Osaic Holdings, Inc. | $4,960.00 | 1.91% | 1.22M | -40,660 | -3.21% | 2025-09-30 |
| Blackrock, Inc. | $3,231.00 | 1.25% | 797,669 | -94,210 | -10.56% | 2025-09-30 |
| Geode Capital Management, Llc | $2,564.00 | 0.99% | 633,067 | -33,124 | -4.97% | 2025-09-30 |
| Marshall Wace, Llp | $2,245.00 | 0.87% | 554,261 | +523,861 | +1,723.23% | 2025-09-30 |
| Wealthspire Advisors, Llc | $1,942.00 | 0.75% | 479,518 | 0 | 0% | 2025-09-30 |
| Susquehanna International Group, Llp | $1,809.00 | 0.7% | 446,578 | +253,378 | +131.15% | 2025-09-30 |
| Lpl Financial Llc | $1,459.00 | 0.56% | 360,268 | -6,710 | -1.83% | 2025-09-30 |
| Geneos Wealth Management Inc. | $1,459.00 | 0.56% | 360,175 | -63,060 | -14.9% | 2025-09-30 |
| Commonwealth Equity Services, Llc | $1,194.00 | 0.46% | 294,901 | +9,487 | +3.32% | 2025-09-30 |